Article info
Inflammatory bowel disease
Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis
- Correspondence to Ulrich Steinhoff, Max-Planck Institute for Infection Biology, Charitéplatz 1, D-10117 Berlin, Germany; steinhoff{at}mpiib-berlin.mpg.de
Citation
Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis
Publication history
- Revised February 3, 2010
- Accepted February 10, 2010
- First published June 25, 2010.
Online issue publication
June 25, 2010
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2010, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.